AAS
AKBA icon

Ameritas Advisory Services’s Akebia Therapeutics AKBA Stock Holding History

Ameritas Advisory Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-437
Closed -$1.59K – 2123
2025
Q2 		$1.59K Buy
+437
New +$1.2K ﹤0.01% 2542
2024
Q2 		– Sell
-12,096
Closed -$15.7K – 899
2024
Q1 		$15.7K Buy
+12,096
New +$19.3K ﹤0.01% 869
2023
Q4 		– Sell
-12,096
Closed -$10.5K – 677
2023
Q3 		$10.5K Hold
12,096
– – ﹤0.01% 802
2023
Q2 		$12.3K Buy
+12,096
New +$11.7K ﹤0.01% 550

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Ameritas Advisory Services's AKBA Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 437 shares — an estimated $1.59K sold.

Ameritas Advisory Services first reported a position in AKBA in Q2 2023 and held it in 4 quarters. The position peaked at $15.7K in Q1 2024. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 437 Akebia Therapeutics shares in Q3 2025, an estimated $1.59K.
  • Ameritas Advisory Services first reported a position in Akebia Therapeutics in Q2 2023 and held it in 4 quarters.
  • Ameritas Advisory Services's Akebia Therapeutics position peaked at $15.7K in Q1 2024.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.